Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

Emma Franco-Mateos,Virginia Souza-Egipsy,Laura García-Estévez,José Pérez-García,María Gion,Laia Garrigós,Patricia Cortez,Cristina Saavedra,Patricia Gómez,Carolina Ortiz,Víctor L. Cruz,Javier Ramos,Javier Cortés,Juan F. Vega

DOI: https://doi.org/10.3390/ijms25073940

IF: 5.6

2024-04-02

International Journal of Molecular Sciences

Abstract:The binding activity of various trastuzumab biosimilars versus the branded trastuzumab towards the glycosylated extracellular domain of the human epidermal growth factor receptor 2 (HER2) target in the presence of pertuzumab was investigated. We employed size exclusion chromatography with tetra-detection methodology to simultaneously determine absolute molecular weight, concentration, molecular size, and intrinsic viscosity. All trastuzumab molecules in solution exhibit analogous behavior in their binary action towards HER2 regardless of the order of addition of trastuzumab/pertuzumab. This analogous behavior of all trastuzumab molecules, including biosimilars, highlights the robustness and consistency of their binding activity towards HER2. Furthermore, the addition of HER2 to a mixture of trastuzumab and pertuzumab leads to increased formation of high-order HER2 complexes, up to concentrations of one order of magnitude higher than in the case of sequential addition. The observed increase suggests a potential synergistic effect between these antibodies, which could enhance their therapeutic efficacy in HER2-positive cancers. These findings underscore the importance of understanding the complex interplay between therapeutic antibodies and their target antigens, providing valuable insights for the development of more effective treatment strategies.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the combined effect of adding Pertuzumab to branded Trastuzumab and Trastuzumab biosimilars in the treatment of HER2 - positive breast cancer. Specifically, the study focused on the binding activities of these antibodies to the HER2 receptor, especially their behaviors when the antibodies were added in different orders, and the properties of the complexes they formed. Through these studies, the authors aimed to understand the synergy between these antibodies and how this synergy affects the treatment effect, thereby providing new insights into the treatment strategies for HER2 - positive breast cancer.

In the paper, the method of size - exclusion chromatography combined with a four - detector (SEC - TD) was used to simultaneously determine the absolute molecular weight, concentration, molecular size, and intrinsic viscosity in order to explore the binding of different Trastuzumab molecules (including their biosimilars) to the HER2 receptor, especially in the presence of Pertuzumab. The study found that all Trastuzumab molecules exhibited similar behaviors in solution regardless of the addition order, indicating that these molecules have a high degree of consistency and stability in their binding activities to HER2. In addition, when HER2 was added to the mixture of Trastuzumab and Pertuzumab, the formation of high - order HER2 complexes increased significantly. This phenomenon may imply the synergy between these two antibodies, which helps to improve the treatment effect. These findings are of great significance for understanding the complex interactions between therapeutic antibodies and their target antigens and provide valuable references for developing more effective treatment strategies.